Hope Pharmaceuticals files two IPR petitions challenging all claims of two Fennec patents relating to sodium thiosulfate
Clients Hope Pharmaceuticals
Jones Day represents Hope Medical Enterprises, Inc. ("Hope Pharmaceuticals") in two petitions for inter partes review ("IPR") at the United States Patent Office's Patent Trial and Appeal Board ("PTAB"). The petitions challenge the validity of all claims of two patents for which Fennec Pharmaceuticals, Inc. is the patent owner or exclusive licensee. The claims are directed to certain forms of sodium thiosulfate and cover composition, synthesis, measurement, and a method of treatment.